Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients

Eleftheria Kampouri, Elizabeth M. Krantz, Hu Xie, Sarah S. Ibrahimi, Erika S. Kiem, Mandeep K. Sekhon, Emily C. Liang, Andrew J. Cowan, Andrew Portuguese, Damian J. Green, Aya Albittar, Jennifer J. Huang, Jordan Gauthier, Ailyn C. Pérez-Osorio, Keith R. Jerome, Danielle M. Zerr, Michael J. Boeckh, Joshua A. Hill

Blood (2024) 144 (5): 490–495.

https://doi.org/10.1182/blood.2024024145

Published: 2024

Includes: Supplemental data

Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood (2024) 143 (26): 2722–2734.

https://doi.org/10.1182/blood.2023023447

Published: 2024

Includes: Supplemental data

Journal Articles

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 3495.

https://doi.org/10.1182/blood-2023-182597

Published: 2023

Journal Articles

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 2143.

https://doi.org/10.1182/blood-2023-174106

Published: 2023

Journal Articles

Phase I/II Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities after CD19-Directed CAR T-Cell Therapy: Trial in Progress

Emily C Liang, Erik L Kimble, Aya Albittar, Jennifer J. Huang, Andrew J Portuguese, Aiko Torkelson, Delaney Kirchmeier, Abigail Chutnik, Barbara Pender, Sylvain Simon, Tony Chour, Evan W. Newell, Rahul Banerjee, David G Maloney, Alexander Spicer, Juho Jalkanen, Alexandre V Hirayama, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 4860.

https://doi.org/10.1182/blood-2023-173152

Published: 2023

Journal Articles

Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel

Aya Albittar, Jenna M Voutsinas, Andrew J Portuguese, Jennifer J. Huang, Emily C Liang, Qian Wu, Xinyi Fan, Alexandre V Hirayama, Erik L Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Filippo Milano, Aude G Chapuis, Ryan D Cassaday, David G Maloney, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 2126.

https://doi.org/10.1182/blood-2023-180128

Published: 2023

Journal Articles

Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, Victor A Chow, Ryan C Lynch, Chaitra S Ujjani, Mazyar Shadman, Brian G Till, Vikram Raghunathan, Edus H Warren, Jordan Gauthier, Stephen D Smith, Taran Gujral, Chihiro Morishima, Qian Wu, Jenna M Voutsinas, Amy Sperling, Joshua Dizon, David G Maloney, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 2129.

https://doi.org/10.1182/blood-2023-183034

Published: 2023

Journal Articles

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Andrew J Portuguese, Aya Albittar, Emily C Liang, Jennifer J. Huang, Alexandre V Hirayama, Erik L Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Hans-Peter Kiem, Filippo Milano, Aude G Chapuis, Folashade Otegbeye, Ryan D Cassaday, David G Maloney, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2023-172978

Published: 2023

Journal Articles

Impact of “Cell-of-Origin” on Outcome after Axicabtagene-Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Aggressive Non-Hodgkin B-Cell Lymphomas

Ilaria Romano, Jordan Gauthier, Ryan C Lynch, Ajay K Gopal, Alexandre V Hirayama, Kikkeri N Naresh, Alireza Torabi, Stephen D Smith, Brian G Till, David G Maloney, Chaitra S Ujjani, Christina Poh, Filippo Milano, Aude G Chapuis, Mazyar Shadman, Lorenzo Iovino

Blood (2023) 142 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2023-181956

Published: 2023

Journal Articles

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Blood (2023) 142 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2023-173202

Published: 2023

Journal Articles

Histone Methylation Mark Analyses Distinguish Carts Manufactured from Distinct Sources and Uncover Novel Transcription Factors Associated with In Vivo Function of Carts after Infusion into DLBCL Patients That Are Not Identified By RNA-Seq

Salvatore Fiorenza, Ye Zheng, Jay Sarthy, Alyssa Sheih, Erik L Kimble, Delaney Kirchmeier, Derek Janssens, Tinh-Doan Phi, Jordan Gauthier, Alexandre V Hirayama, Qian Wu, Raphael Gottardo, Stanley R. Riddell, David G Maloney, Steven Henikoff, Cameron J. Turtle

Blood (2023) 142 (Supplement 1): 3454.

https://doi.org/10.1182/blood-2023-188269

Published: 2023

Journal Articles

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Blood (2023) 142 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2023-172695

Published: 2023

Journal Articles

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 6860.

https://doi.org/10.1182/blood-2023-181273

Published: 2023

Journal Articles

Phenotypic Analysis of Baseline T cell Subsets and Third Generation CD20 Targeted CAR T cell Products for Treatment of Relapsed/Refractory Follicular Lymphoma

George Mo, Sang Yun Lee, Jenna M Voutsinas, Qian Wu, Dong Hoon Lee, Jordan Gauthier, Alexandre V Hirayama, David G Maloney, Mazyar Shadman, Brian G Till

Blood (2023) 142 (Supplement 1): 6877.

https://doi.org/10.1182/blood-2023-180446

Published: 2023

Journal Articles

Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 5254–5257.

https://doi.org/10.1182/blood-2022-165437

Published: 2022

Journal Articles

Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Alexandre Vinaud Hirayama, Salvatore Fiorenza, Jordan Gauthier, Jenna M. Voutsinas, Qian Vicky Wu, Erik L. Kimble, Barbara S. Pender, Delaney R. Kirchmeier, Henna A. Di, Ryan D. Cassaday, Aude G. Chapuis, Damian J. Green, Hans-Peter Kiem, Filippo Milano, Mazyar Shadman, Brian G. Till, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2022) 140 (Supplement 1): 7447–7449.

https://doi.org/10.1182/blood-2022-168185

Published: 2022

Journal Articles

Impact of Hematopoietic Cell Transplantation after CAR T-Cell Therapy for B-ALL: Comparison of Statistical Models and Survival Curves By a Novel R Shiny Tool

Yimei Li, Yang Qiao, Jordan Gauthier, Qiang Zhang, Jenna M. Voutsinas, Wendy Leisenring, Ted A. Gooley, Corinne Summers, Alexandre Vinaud Hirayama, Cameron J. Turtle, Rebecca A Gardner, Qian Vicky Wu

Blood (2022) 140 (Supplement 1): 12947–12949.

https://doi.org/10.1182/blood-2022-167264

Published: 2022

Journal Articles

Predicted Fludarabine Exposure Is Independently Associated with CRS and ICANS after CD19 CAR T-Cell Therapy

Ivan J. Huang, Rosa Yeh, Karen Sweiss, Pritesh Patel, Alexandre Vinaud Hirayama, Erik L. Kimble, Krishna R. Juluri, Mazyar Shadman, Cameron J. Turtle, David G. Maloney, Jordan Gauthier

Blood (2022) 140 (Supplement 1): 12725–12727.

https://doi.org/10.1182/blood-2022-156751

Published: 2022

Journal Articles

Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study

Blood (2022) 140 (Supplement 1): 2048–2050.

https://doi.org/10.1182/blood-2022-169872

Published: 2022

Journal Articles

CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study

Nicolas Gazeau, Salvatore Fiorenza, Erik L. Kimble, Alexandre Vinaud Hirayama, Barbara S. Pender, Henna A. Di, Delaney R. Kirchmeier, Brian G. Till, Mazyar Shadman, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle, Jordan Gauthier

Blood (2022) 140 (Supplement 1): 10363–10365.

https://doi.org/10.1182/blood-2022-157826

Published: 2022

NARROW

Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Phase I/II Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities after CD19-Directed CAR T-Cell Therapy: Trial in Progress

Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel

Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Impact of “Cell-of-Origin” on Outcome after Axicabtagene-Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Aggressive Non-Hodgkin B-Cell Lymphomas

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Histone Methylation Mark Analyses Distinguish Carts Manufactured from Distinct Sources and Uncover Novel Transcription Factors Associated with In Vivo Function of Carts after Infusion into DLBCL Patients That Are Not Identified By RNA-Seq

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Phenotypic Analysis of Baseline T cell Subsets and Third Generation CD20 Targeted CAR T cell Products for Treatment of Relapsed/Refractory Follicular Lymphoma

Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms

Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Impact of Hematopoietic Cell Transplantation after CAR T-Cell Therapy for B-ALL: Comparison of Statistical Models and Survival Curves By a Novel R Shiny Tool

Predicted Fludarabine Exposure Is Independently Associated with CRS and ICANS after CD19 CAR T-Cell Therapy

Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study

CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only